Manufacturers make resubmission to FDA for XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) for macular oedema associated with uveitis

The resubmission is following a previous refusal for market authorisation in 2019 by the FDA. Manufacturers state that a response has been made to all the issues raised by the FDA. The technology is designed to deliver triamcinolone to the suprachoroidal space.

Source:

Biospace Inc.